INT311479

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2010
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 4
Total Number 6
Disease Relevance 4.92
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Mllt1) nucleus (Mllt1) cytoplasm (Mllt1)
Mllt1 (Mus musculus)
Pain Link Frequency Relevance Heat
Lamotrigine 522 100.00 Very High Very High Very High
antiepileptic Drug 96 99.20 Very High Very High Very High
Neuropathic pain 4 98.64 Very High Very High Very High
carbamazepine 52 97.40 Very High Very High Very High
cocaine 4 93.16 High High
addiction 4 92.84 High High
headache 16 89.04 High High
anticonvulsant 18 5.00 Very Low Very Low Very Low
Gabapentin 12 5.00 Very Low Very Low Very Low
Glutamate 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cognitive Disorder 4 99.60 Very High Very High Very High
Manic Depressive Disorder 4 99.48 Very High Very High Very High
Fatigue 4 99.32 Very High Very High Very High
Neuropathic Pain 4 98.64 Very High Very High Very High
Syndrome 42 98.60 Very High Very High Very High
Partial Seizures 40 98.24 Very High Very High Very High
Convulsion 220 98.06 Very High Very High Very High
Exanthema 74 94.96 High High
Disease 6 93.64 High High
Drug Dependence 4 93.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With regards to quality of life, approximately 30% of patients reported tiredness and cognition problems, however, LTG seems to affect the quality of life much less than other AEDs such as CBZ, PHT, topiramate, and VPA.3
Spec (seems) Gene_expression (seems) of LTG associated with cognitive disorder, lamotrigine, fatigue, antiepileptic drug and carbamazepine
1) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 1.29 Pain Relevance 0.50
LTG-IR was initially introduced in the form of adjunctive therapy in adult partial epilepsies and subsequently in children above the age of 2 years, however, its efficacy has been shown down to one month of age.3 During clinical trials in adults this AED was applied in daily dosages of 200–500 mg.
Gene_expression (introduced) of LTG associated with lamotrigine and partial seizures
2) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.44 Pain Relevance 0.24
g/mL were observed since, in most cases, LTG was added to enzyme-inducing antiepileptic drugs (EIAEDs).3 It is remarkable that even serum concentrations of 15 ?
Gene_expression (added) of LTG associated with lamotrigine and antiepileptic drug
3) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.73 Pain Relevance 0.46
g/mL are generally well tolerated.3 LTG is also indicated against generalized seizures in Lennox–Gastaut syndrome and has been approved for conversion to monotherapy.3 Interestingly, LTG has been found to be effective in treating bipolar disorder and neuropathic pain syndromes.3,20 More studies are necessary to evaluate its possible efficacy in the treatment of Alzheimer’s disease and cocaine addiction.20
Gene_expression (effective) of LTG associated with addiction, manic depressive disorder, convulsion, syndrome, neuropathic pain, lamotrigine, disease and cocaine
4) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.83 Pain Relevance 0.61
The straightforward conversion between LTG-IR and LTG-XR dosing is also advantageous.
Gene_expression (dosing) of LTG-IR
5) Confidence 0.55 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.81 Pain Relevance 0.29
The straightforward conversion between LTG-IR and LTG-XR dosing is also advantageous.
Gene_expression (dosing) of LTG-XR
6) Confidence 0.55 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.81 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox